HOME >> BIOLOGY >> NEWS
Novel therapeutic bortezomib moves to phase II trial in lung cancer patients

(NEW ORLEANS) -- A three-drug combination including the novel molecularly targeted agent bortezomib, the first drug in its class, proved well-tolerated and showed promising efficacy in patients with advanced non-small cell lung cancer, according to phase I trial results reported Saturday at the annual meeting of the American Society of Clinical Oncologists.

The triple-therapy regimen will now be tested nationally in a phase II trial as first-line therapy for advanced non-small cell lung cancer. Angela Davies, assistant professor of hematology/oncology and principal investigator of the phase I trial, will lead the phase II trial as well.

The regimen consists of bortezomib, gemcitabine and carboplatin. Gemcitabine and carboplatin represent an accepted first-line treatment combination for advanced non-small cell lung cancer.

In the small phase I trial, the three drugs were administered on a similar schedule. Out of 12 patients, four had a partial response and seven had stable disease.

In the larger phase II trial, which will enroll 99 patients, the drugs will be given sequentially, with bortezomib following the chemotherapy drugs. Preclinical research at UC Davis Cancer Center suggests that giving bortezomib last may be more effective than giving it first or at the same time.

Bortezomib is a proteasome inhibitor that blocks the signals cancer cells rely on to degrade cellular proteins. The result is a buildup of proteins that hastens cell death.

Bortezomib has been approved by the Food and Drug Administration for the treatment of multiple myeloma, but had not been tested before in non-small cell lung cancer.

"Bortezomib is an exciting therapeutic, and we're encouraged that we've been able to take this promising three-drug combination immediately from phase I to phase II," Davies said.

Of the estimated 175,000 new cases of lung cancer diagnosed in the United States each year, nearly 80 percent are n
'"/>

Contact: Claudia Morain
530-219-5053
University of California, Davis - Health System
5-Jun-2004


Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel approaches to current cellular therapies continue progress toward disease prevention
3. Novel therapies show promise against myeloid leukemia
4. Novel sensors help clear the air
5. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
6. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
7. Novel therapeutic target identified in fight against Rheumatoid Arthritis
8. Novel bacterium detoxifies chlorinated pollutants
9. Novel flu vaccine shows promise in mice
10. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician
11. Novel method identifies hidden genes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/17/2019)... ... 16, 2019 , ... At nearly eleven years old, Seve, a white Golden ... owner, in the last year or so, he was a little “gimpy” and occasionally ... Echevarria of VCA University Animal Hospital in Dallas, diagnosed him with severe ...
(Date:7/9/2019)... , ... July 09, 2019 , ... ... Tx Genetic Research into its incubator program. The founder and CEO of Tx ... improve the lives of those suffering from epithelial connective tissue disorders. , “We ...
(Date:6/27/2019)... ... June 27, 2019 , ... Lighting designers from integrated design firm ... which honored the designers for creating both engaging and energy efficient lighting systems. , ... an office tower in San Diego, California earned an IES Illumination Award of Merit ...
Breaking Biology News(10 mins):
(Date:5/31/2019)... NEWPORT BEACH, Calif. (PRWEB) , ... May 30, ... ... the future of neurotoxins, is pleased to announce the strategic acquisition of Metabiologics, ... for research. The acquisition provides Object exclusive ownership and commercialization rights to a ...
(Date:5/15/2019)... ... May 15, 2019 , ... Milton Hershey School® has named William ... work within the biomedical industry, where he is changing lives by creating solutions to ... “William Harding epitomizes the vision of our founders – Milton and Catherine Hershey – ...
(Date:5/8/2019)... ... 2019 , ... Standing at 16.2 hands, Atlas is on the large side for a Quarter ... barrel racing, among other activities. When loping around a corner in late 2017, Atlas ... busy horse to only being able to walk. Fortunately Atlas’ owner, Kelly, sought the ...
(Date:5/2/2019)... ... April 30, 2019 , ... ... standard, REPROCELL USA Inc. has demonstrated its ability to provide various services ... aims to enhance customer satisfaction through the effective implementation of its quality ...
Breaking Biology Technology:
Cached News: